Aberrant expression of ERG promotes resistance to combined PI3K and AR pathway inhibition through maintenance of AR target genes

Based on our previous work defining the molecular rationale for combined targeting of the PI3K and AR pathways in PTEN loss prostate cancer, the first clinical trial was recently reported demonstrating a significant benefit for combination therapy in patients with metastatic prostate cancer. In this...

Full description

Saved in:
Bibliographic Details
Published in:Mol Cancer Ther
Main Authors: Mao, Ninghui, Gao, Dong, Hu, Wenhuo, Hieronymus, Haley, Wang, Shangqian, Lee, Young Sun, Lee, Cindy, Choi, Danielle, Gopalan, Anuradha, Chen, Yu, Carver, Brett S
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726496/
https://ncbi.nlm.nih.gov/pubmed/31296553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-1386
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items